FDA Issues Warning for Fluoroquinolone Drugs Levaquin, Cipro, Avelox
The FDA issued a safety warning on May 12, 2016, to restrict the use of fluoroquinolone antibacterial drugs including Levaquin, Cipro, and Avelox. This new safety announcement will restrict use of Levaquin and other fluoroquinolone drugs and require that they not be used to treat patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. The FDA indicates that fluoroquinolones should only be reserved for patients who do not have alternative treatment options.
Three years ago the FDA issued a safety announcement requiring label changes to fluoroquinolone drugs for an increased risk for potentially permanent nerve damage, or peripheral neuropathy. Some common brands of drugs that contain fluoroquinolone or quinolone include Levaquin, Cipro, Avelox, Noroxin, Floxin, and Factive.
Thousands of lawsuits have been filed in state and federal courts across the nation by patients who experienced severe nerve damage after taking Levaquin and other quinolone-containing drugs like Cipro and Avelox. If you or someone you know has taken Levaquin or another quinolone-containing antibiotic and experienced severe nerve damage, contact us. Our product liability attorneys have experience litigating personal injury claims against large drug manufacturers and can provide you with a free case evaluation.